Alethia™ Group B Streptococcus / illumigene Group B Streptococcus by Meridian Bioscience

Catalog Number: 280350

Product Description

DNA amplification assay for the detection of Group B Streptococcus (GBS) in vaginal/rectal antepartum specimens.

Fully comply with the 2010 CDC guidelines by using the most sensitive assay on the market for Group B Streptococcus detection. The simplified procedure allows labs to report accurate, definitive results in less time than culture. This simple, cost-effective menu addition make this innovative test ideal for helping in early diagnosis and proper management of this preventable disease.

Alethia™ Group B <em>Streptococcus</em> / illumigene Group B <em>Streptococcus</em> by Meridian Bioscience

Double click on above image to view full picture

Zoom Out
Zoom In

More Views


Related Products

  • Details

    Product Specification

    illumigene Catalog #: 280350
    Alethia Catalog #: 480350
    Assay Format: Isothermal Nucleic Acid Amplification Assay
    Kit Size: 50 tests
    Specimen Type: Vaginal/rectal swab
    Sensitivity: 97.4%
    Specificity: 92.3%
    Time to Results (TAT): Less than 1 hour after enrichment step
    Kit Storage Requirements: 2-27°C
    Shelf Life: 18 months
    Manufacturer: Meridian Bioscience, Inc.
    GMDN: 30711
    CE: YES
    FDA: YES
    Availability: European Union
    Other countries: Please Contact Us or visit our Distributor page.


    Customer Reviews

    "Testing GBS with the illumigene molecular method proved to be a very sensitive method compared to culture on blood plate agar. With illumigene GBS we get more positive results and no false negative results. Especially for samples with low inoculum of GBS, illumigene proved to be a faster and more accurate method compared to culture."

    Martina Kavcic, Dr. Med., spec. klinicne mikrobiologije, vodja laboratorija
    Ksenja Maršic, Microbiologist, Institute of Public Health Koper, Slovenia

    "...carrot broth only detects hemolytic strains of GBS and the blood plate did not show "typical" colonies of GBS, the patient was inaccurately determined to be "negative for GBS". The reason our lab had decided to evaluate the illumigene GBS methodology was for this very reason. We did not want to miss non-hemolytic GBS. Our correlation studies proved our need to change to the illumigene GBS method."

    Amanda Smith, MT, ASCP, The Pathology Laboratory, LA, USA